<DOC>
	<DOCNO>NCT00048724</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy PEG-Intron vs. treatment prevention disease progression adult subject compensate cirrhosis secondary chronic hepatitis C , fail respond therapy interferon plus ribavirin .</brief_summary>
	<brief_title>Peg-Intron Prevention Disease Progress Chronic Hepatitis C Patients With Cirrhosis ( Study P02569 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age entry 1865 year ; Nonresponders previous treatment ( minimum 3 month ) alpha interferon plus ribavirin ; Liver biopsy demonstrate cirrhosis Any cause liver disease chronic hepatitis C ; History presence complication cirrhosis ; Alcohol illicit drug abuse treatment methadone within past 2 year ; Diseases condition could interfere participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C ; Cirrhosis</keyword>
</DOC>